Imaging Bio Share Chat (IBAI)

... no-one is here long-term, Tyke!! haha!!

-- BB --

Just seen the value of today’s trade. This amount 124657 is getting quite repetitive. Maybe our 1 share trade person is trying to send another message apart from they don’t have a “3” button.

Thanks

Phil

Trevor will get relelected whatever and he knows that. We can’t even muster commitment from 10% of the shares against the nominal value change. Trevor is here for the long term.

Thanks

T

Https://www.investegate.co.uk/announcement/rns/truetide-plc--true/final-results-and-notice-of-agm/9645603

Trevor Brown appears to be concentrating fully on the TRUE investee companies. Well, H1 has now ended for IBAI. Let's see whether we get an IBAI trading update this month, confirming a revenue increase in line or ahead of expectations.

Trevor knows he has to deliver in this financial year, as he will be up for re election as a director. Shareholders need to be in a position to vote him out if he doesn't. That means increasing their holdings or hoping a third party enters with a view to acquiring a 30% position.

Personally, I do not want to see any placing at 0.75p, let alone 0.5p. So we need a news driven H2 and a share price rising to 1.5p.

Just waiting for either the interim results (August) which should show in their words a “step change” to profitability

Or our 1 share at a time purchaser gets bored and disappears.

Thanks

Kane - the nominal value has already been adjusted, see my post below on 25th June.

- what are we waiting for? - confirmation of "Group-wide cost savings", an idea of what "Kirkstall's accelerating sales" brings to the table, and confirmation that "IB's next-generation platforms creates a clear path to profitability in 2026."

-- what are we hoping for? - the above confirmation via more frequent trading updates. Possibly a quarter update?

-- timeline - "profitability in 2026"

Literally their words.

I would say we’re waiting for the nominal value to be adjusted and a sharp fall in share price back to 0.005 where the bod and their insiders will fill their boots then proceed to announce very rampy rns to then sell their shares to unsuspecting personal investors. All while releasing very little information and doing no interviews

OK - probably for dear Tyke ...

-- what are we waiting for?

-- what are we hoping for?

-- timeline

Thank you!

-- BB --

Again agreed but the headline figure puts off any body wanting to buy or sell.

If you have 33%+ spread showing people are going to think something is not right.

Interesting how TB may have done publicity for Truetide but not IBAI. Would that have a positive effect? Greater trust is needed by shareholders and that trust has to be gained. Very interesting how TB is viewed differently on the boards for Truetide and IBAI. Previously Braveheart holders have been rewarded so are more trusting and forgiving to variations in the sp. IBAI shareholders have never seen any rewards so obviously are less trusting or forgiving.

Thanks

T

Whatever the spread, if you look at the prices of bargains done, they are always much narrower

Agreed but what would the sp be now if the market makers had actually not been so greedy with the spread when we had the latest mini rise? We had people genuinely interested with the last few RNSs but their spread was ridiculous and nobody was willing to sell.

Something is “broken” maybe trust, fingers burnt before etc but people are not going to sell any reasonable volume unless they get a fair price

Thanks

Those shares were also someone’s sell, I promise you, the market makers do not roll their own

Currently I would say they could be classed as big trades for this company. When the mcap is 8 figures then I would totally agree but at the moment any buys are welcome.

Thanks

The board had the numbers to win the vote. End of story, it has happened.

Thanks Corry.

The capital reduction (par/nominal value change) and the corresponding changes to the Memorandum and Articles of Association were registered with the Jersey Financial Services Commission yesterday, 24th June, so that's now official and complete.

Just to pre-empt the next likely question - no, they don't need to RNS doing that as the publication of the AGM results showing the resolutions were passed is deemed sufficient notice. Very rare for any company to ever RNS 'companies house' type filings as it's normally just routine admin.

Kane

I don’t think people on here are sticking up for TB. I and others may be being polite but that should not be confused for “sticking up for”. I am sure many agree with your sentiments but I believe we are not going to achieve anything by just venting on here. Ask the board your questions and see if you get a reply. You may or you may not but at least you can say you tried and then maybe let this board know.

When we acted united and people “committed” their shares we got some more information from the company. If we put our United heads above the parapet we may slowly achieve change.

Then again you may say we achieved nothing, which you are more than entitled to put. But we said how many shares we owned and tried to act as a group.

Thanks

If you think people on here are sticking up for Trevor then you maybe interested in looking at the Truetide board pages. He is highly thought of by quite a few over there.

Thanks

T

RJH you are not the only one. There are many others that have been failed by these crooks in charge here. The sooner they fek off and appoint someone who has a clue about running a publicly listed company. They are treating this as if it’s a private company.

Trevor is a parasite on this company and needs to stand down and appoint a professional with a proven track record. We might then see a recovery here. Nothing has or is going to change.

People sticking up or supporting these crooks should be ashamed of yourself.

The only question Trevor needs to answer is when is he going to get the share price back to 5p? He caused this mess so he needs to sort it out. Mike is needs to grow a pair for the sake of our investments and force change.

They need to update ALL their shareholders on what is happening with the nominal value changes. As new investors will be put off rightly so.

The bod need to sort this mess out and give a clear plan going forward how THEY are going to get the share price back to where it was before Trevor sold his family’s shares.

Can anything be worst than our illustrious leader? The guy should be strung up. Made such a loss there's no point selling my holdings. Spoke to MS on the phone last year, sounds capable and up for it. COME ON IBAI grow some!

Seems to have disappeared so maybe these lyrics are relevant “ And you really don't remember, was it something that he said?

Are the voices in your head calling, Gloria?”

Thanks

Thanks

Max

Let’s hope you (and AI) are correct. But at what price would they sell Nimble? There does seem to be a case made for them working together. It’s a pity the new MO means no updates from Mike until signed, sealed and delivered. Maybe look out for a tweet or whatever the similar thing is on LinkedIn. That could be a good indicator of collaboration rather than competition.

Thanks

Tyke

I’ve come up with a reasoning why Xcures could bug IB Nimble ,

https://www.google.com/search?q=could+Xcures+buy+Imaging+biometrics+IB+Nimble+to+fig+into+their+scheme&client=safari&hs=iFTV&sca_esv=bf958c3e0f55ada9&hl=en-gb&sxsrf=APpeQnuH-uVUZ3VUoESaj8nm-w4ebHyYkA%3A1782328877173&udm=50&fbs=ABfTbFXmzBGw9LECshVETHbdczUekrr4P3jxmDQ00QvQP6rDCfvRDF3m1JTFCpkx8Z4iq9wmRUnBSPrugc0w7UKbsTL-4FLhY96_fK19s6RnZ1OmWBlUrR31pAHfItcrzISdtUKNq8RwFchRndCyBeUNgiOL-zSVk7MfE72ucRgTNEGAZqgBQvsYe4xg-CsjEsRPOuUlL7w7UAOdcZ8htf89ICFNR1xml0CsQ-4-sCLJDHlvFOMC7so&aep=1&ntc=1&sa=X&ved=2ahUKEwi44eK8zKCVAxWLXUEAHZqmMJIQ2J8OegQIDRAE&biw=414&bih=744&dpr=2&mstk=AUtExfCf8C-TjgB6PdijQYktIzqfEuIzJ9Z8FjVzHio5G8julNs_1N2mFQxR43nqsbbCnDc9Y_EL9ZnlAHv2XELJ_MN_YUE2dze07EptIlxEzWVK-PF0O8g3QBBRiP9eR5yMXGVvEU88g6T_FOmJp1o-xnZ-HRMqzO4Ly71839dnaPXVGljjfl8QPXFoN97TdUdj7TZwWC22A4YRiMzFlyqit12PVxKW7TOwIEJhjMcxfiWzdiG_GLpaW-eqSx77qP9xvlgGS0D-NGlv7bmRh3fDPJgfejRDx9cOxuvqPg2ZnnR7eNi2bBvlFaO01seHbP5vGaoWIeA8b2z_9A&csuir=1&mtid=NC48atX1Ja2YhbIP7b3-sAE

Gloria

Are you sure it wasn’t one of the other forums you have claimed to been informed by her on. I have to give credit to you, you have used multiple variations of the same post. Or somebody on here will probably tell me you used AI and maybe copied and pasted.

You didn’t leave the WhatsApp number on our board. I feel like we have missed out.

Is Laura related to the late 2 jags/2 jabs? I am sure he would have had a few choice words for you wasting our time.

Thanks

Max

Sounds more like a competitor for IB Nimble to me. But raising $70+ sounds good to me. They can buy Nimble for that if they want. A nice birthday present for TB.

Thanks

Gloria

I would love you to show us all who on this forum recommended Laura G Prescott? A link to the post would suffice.

Was is it a poster called Semantic?

Thanks in advance

To illustrate this a bit further, just for general interest:

The London Stock Exchange (LSX) is currently showing an mcap of £1.57m which it has done since this morning. That is based on last night’s closing auction UT of 0.635p. LSX only update their mcap on the public screens once a day, overnight before market open.

The £1.48m mcap shown above (-5.5%) was based on an intra-day auction UT of 0.6p.

There was no closing auction UT tonight so the official closing price is set at the mid point of the spread* at 0.7p. LSX will then show a mcap of £1.73m (+10.2% from yesterday) all day tomorrow.

All three of those ‘values’ are generated purely by the technical rules within databases that determine which price to adopt and at what time. None of them reflect any meaningful trading, and there has been no activity from the company in that 24 hour period to influence the mcap.

So you can ask yourself - which of those three is a truer reflection of the value of the company at this time, if any?

And will tomorrow’s close be any more meaningful if the spread shifts by 0.1p, or the closing UT is 0.6p? Or if just 10 shares are exchanged in a UT that sets an errant closing price of 0.8p and thus a mcap of £2m, only to fall back again the end of the following day?

https://www.londonstockexchange.com/stock/IBAI/imaging-biometrics-limited/company-page

----------

Technical intra-day or even day to day movements in mcap, and/or on small volume/low value trading, will not tell anything meaningful about the situation because of how this is displayed.

The trend is, as always, your friend ;o) And so is a very cold glass of beer right now so I will leave with these musings.

* simplified for illustration purposes

Tyke - ignore the mcap as shown on this website, it's unduly influenced by the same anomaly that Phil mentions below. The 'current' SP of 0.6p is a system anomaly because it is taken from the UT at 09:06:26 - in the same way as the closing price is often taken from a UT, or the mid price if there is no UT at end of day - and so the mcap is 'mis'-displayed in the database here as 246.7m shares x 0.6p. A truer reflection would be based on the mid-price but even that is problematic on an intra-day basis.

You can't make a reasonable assessment of pricing on a very low liquidity small-cap like this by looking at very short time frames, and I sincerely hope that no-one is making any investment decisions solely based on what is displayed on this unofficial, unregulated website which is often missing trade data.

The key elements are the overall volume, price and company value OVER TIME and the TREND that they create (caps just for emphasis) - and that's a whole other discussion had many times over as to what the catalysts for that will be.

Phil

Thanks, I am more interested in looking at the effect and reasons all this movement has on the mcap which has now dropped to £1.48m. I prefer to use that as a point of reference as the spread is so ridiculous.

Just wondered if level 2 showed anything interesting.

Thanks once again

T

Tyke,

We have the same conversation a dozen times a year, which is amusing.

As we know, today's movement is calculated using the last trade yesterday. As that was an after hours 49k @ 0.635p, today's movement (using 904 @ 0.63p) is a rounded 0.01p- which is 1.56%-

Current L2 is again unchanged:-

3 900k 0.6 v 0.8 600k 2

2 600k 0.5 v 1.1 600k 2

1 300k 0.45 v 1.2 300k 1

v 1.5 300k 1

As ever, you can trade inside the spread.

Phil

Buys far outweighed sells yesterday drop 9%

Today similar pattern and dropped 5% so.

Phil any idea what’s happening with level 2 etc or just MMs having a laugh at our expense again?

Thanks

Thanks Mallettp

No need to even suggest humble pie. With this company all company sense, normal operating procedures etc goes out of the window. We all “guess” what we think is happening then either nothing happens or the exact opposite does.

Only we are all sure of is the tech side is worth far more than the current mcap (hence the lack of sellers) and we all hope the GaM side is worth more than that.

Thank you and have a good weekend

T

Well I was clearly wrong about them waiting for the phase 0 results - so humble pie for me.

It still seems they are trying to add value without spending a great deal.. hence the restart of the early access program. .Getting data from another 20 people to add to the phase 1 trialists boosts the sample.size - medium-sized oncology player might be interested. If the radiosensitizer pre-clinical studies being undertaken demonstrate a combination effect, that would make the drug more attractive as an adjunct therapy. It's also a lower risk proposition than a monotherapy. The vivan fruit fly screaming might also generate some excitement if GaM shows a signal in high prevelence cancers.

All conjecture on my part tho..

Again why are they not publicising this more? They are only informing a few prospective customers that follow them. We need a wider customer base that generates income.

World leading tech at Poundland prices!

Thanks Max

Have a good weekend everyone

Thanks

Https://www.linkedin.com/posts/quasi-vivo-for-organ-on-a-chip-the-researchers-share-7471135270583599104-sicJ/?utm_source=share&utm_medium=member_ios&rcm=ACoAAAkyjQ0B7bMMkoLn8XD8s2HLk9vizWE-zfc

Previously that big sell would have dropped the sp but that hasn’t happened (yet). So why not this time?

Thanks

Here’s an observation. Mike does publicity etc for IB news etc. Who does publicity for Kirkstall? That post Max found sums up it up.

A great innovation but who actually knows about it? No RNS. It is not on the Kirkstall website home page (https://kirkstall.com/) you have to click “more papers” to view it.

Why are we not publicising all our products more? Do we actually have anybody in charge of publicity or even responsible for publicity?

I am going to go out on a limb here and say greater publicity would equal a greater share price. It seems a no brainer to me and I would love somebody from the company including/or Semantic to explain why we don’t do it.

I believe semantic said something like a targeted audience for our products before so not worth doing (apologies if incorrect). That may well be the case but that doesn’t encourage new share holders. Plus the old strategy obviously hasn’t worked well if we are struggling to break even.

My rant for the day over.

Thanks

The organisations interested paragraph

I think is new , sorry I reposted it was try g to highlight it

Are the last few paragraphs new?

Thanks

Glioblastoma Research Update:

Gallium Maltolate Phase 1 Results

We are pleased to announce the publication of results from the first-in-human Phase 1 clinical trial evaluating oral gallium maltolate (GaM) in patients with recurrent or treatment-refractory glioblastoma.

Key findings included:

GaM was well tolerated across daily doses ranging from 500 to 2,500 mg.

Treatment-related adverse events were limited to Grade 1–2 toxicities (primarily gastrointestinal/diarrhea), with no Grade ≥3 events observed.

No nephrotoxicity was observed.

The recommended Phase 2 dose was established at 2,000 mg daily.

Among 22 patients evaluable for tumor response, median overall survival was 16 months from the start of GaM treatment.

High proportion of extended survivors: 59% (13/22) of evaluable patients survived beyond 12 months, exceeding typical expectations in the recurrent setting.

One patient achieved a sustained partial response and remains on treatment (> 33 cycles at the time of publication).

As a small, nonrandomized Phase 1 dose-escalation trial, the study was not designed to establish efficacy. However, the findings support further evaluation of GaM in a statistically powered Phase 2 clinical trial.

Read the peer-reviewed publication in Neuro-Oncology Advances

The Phase 1 findings support the need for continued evaluation of gallium maltolate in recurrent glioblastoma through a statistically powered Phase 2 clinical trial.

Organizations interested in contributing to the next phase of clinical development are invited to contact Imaging Biometrics for additional information. eap@imagingbiometrics.com

Gallium maltolate remains investigational and has not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

Organizations interested in contributing to the next phase of clinical development are invited to contact Imaging Biometrics for additional information. eap@imagingbiometrics.com

Red you could always buy a few million more cheaply if you don’t mind crossing the 3% threshold. Maybe TB would offer you a seat on the board? Unfortunately that would then make you the enemy in some people’s eyes on this board.

No RNS outlining TR1 so not an insider selling.

Maybe one of the posters who only appear’s when we get a rise. They might have lost interest until the next time. Then showjumper will turn up again. If they fully believed in the share they could see this drop back as a buying opportunity.

Come on Mike let’s have some more positive news please. I don’t suppose we get contract news anymore if all bundled in with GEHC stuff. Something we don’t know about yet would be good.

Thanks

Truetide dropping as well today

... along ... or down .... :(

-- BB --

Well it was exciting the last few days but those few bigs sell have definitely stopped the increase. It looks like we are going to be staying the same. I can’t think of any news we are anticipating until we get the mid year’s. So unless Mike has something we don’t know about yet hidden up his sleeve we may be in for a period of just drifting along again.

Thanks

New MO just release RNS every now and then and nothing else

Thanks

Nothing posted by IB on social media .

Depends on who the seller is?

One news update now showing Max but unfortunately too late to stop the drop in sp. Let’s see what happens tomorrow, continued steady increase, stays the same or falls back to around 0.5p? You can’t blame the BoD for this. Two excellent RNSs but some people selling 4 lots of 500k knocks us back down. The brief flirtation with 1p+ was quite good for once.

Good luck everyone

Thanks

I wonder if we will get any promotional media this afternoon , proactive interview would be good , or MCW in control ?

Well the market has shown it agreed with my earlier summing up of the prospects of any future trials of this.

Still some managed to exit without more pain.

What, you think uk punters are about as clueless about Euromillions as they are about investing?

🤥 liar

Ahahaha. Down 20%.

Welcome to not-so-great britain, where investors have a better understanding of Euromillions than stocks.

They have plenty of choices to make at these levels and unless one of believes they could be onto something big they keep an eye out for better opportunities like investor do with stocks, often getting it wrong, as most of us do at times.

Alif

That’s the EAP not the trial, thanks

Good to see the website has been updated already to show available.

Thanks

I think trials are ongoing subject to getting enough patients who meet eligibility criteria, (existing and a limited number of new patients.)

From US clinical trials site

Further study of GAM . 3 locations miami Florida, NYC, lincoln Nebraska

Last update -2026-06-08

https://clinicaltrials.gov/study/NCT06404034

IBAI is sponsor, collaborators : Xcures

We also need patience. GLA

After those three 500k sells we needed to assess the next step. Interestingly, the offer has jumped higher to 0.85p (you can trade inside), at circa 9.25pm. Let's see if we get a large delayed buy in an hours time.

Rerate is coming

Looks like we are going to open with a very bullish 4 v 1

Https://academic.oup.com/noa/advance-article/doi/10.1093/noajnl/vdag154/8703985?searchresult=1

Thanks Red

Cautious I agree but we know how this can work sometimes.

Let’s see what happens, Max fingers are still crossed?

Thanks

Can’t seem to buy any!

Tyke I wouldn’t have thought the EAP would cost a great deal and I believe that was the idea of the Musella foundation and also the patients paying towards the costs!!!

Being cynical the 3 sells suppress the price keeping the 7 day VWAP in check

Great call below Bunsen burner ! Don't cross ramp again please ! Down 70 percentage so far today

SBDS is my main pick. Can see a breakout there soon. With customers like Apple and Mars, a market cap under £5m with over £10m revenues and being cash generative for the first time in their history end of Q2, you’d like to think there’s room to move significantly higher! 20% growth too!

Surely BLUE all day long after this RNS

RNS OUT

Truetide True hold just under 30% of this stock so if you play Ibai have a nibble of True because all their investments easily cover their market cap and they have some exciting products of their own as well where they own 100%.

Today’s RNS (Tuesday, June 9) is a significant milestone because it officially shifts the narrative from subjective corporate optimism to hard, peer-reviewed science published in a top-tier medical journal. The company announced the formal publication of its Phase 1 clinical trial results for oral Gallium Maltolate (GaM) in the prestigious journal Neuro-Oncology Advances, alongside the immediate reopening of its Expanded Access Programme. 

The data provides a strong foundation for the company's future for several key reasons:

Any small biotech can release a positive company presentation, but getting data published in a leading peer-reviewed journal like Neuro-Oncology Advances is completely different. It means an independent panel of world-class oncologists and neuroscientists thoroughly vetted the trial’s data, methodology, and conclusions. This validation makes it far easier for IBAI to pitch to institutional partners, clinicians, and large pharmaceutical buyers.  While Phase 1 trials are technically designed only to test safety and establish dosing, IBAI’s trial achieved an exceptionally rare secondary win: clear signals of clinical efficacy. CEO Trevor Brown noted that the data showed:

A safe, established dosing regimen for patients with recurrent or treatment-refractory glioblastoma (GBM)—the most aggressive form of brain cancer. 

Visible proof of biological and clinical activity. 

Durable disease stabilization and prolonged survival in select patients. 

In a cancer market where the standard survival timeline is brutally short, showing any prolonged survival in a Phase 1 safety trial is a massive achievement. By immediately reopening the EAP, IBAI can provide GaM to patients outside of formal clinical trial settings. For investors, this is highly strategic, It keeps the drug actively moving through clinical hands, building real-world evidence and doctor familiarity.

It keeps IBAI in the spotlight within the neuro-oncology community as they prepare the groundwork for a larger Phase 2 study. It’s going to 💥 boom!

Now watch the volume come through today. It will be interesting to see if there are those wanting to build a holding, rather than trade it.

Selling yesterday may well have been a mistake for some, although a profit will always be a profit.

We will know shortly.

Given the RNS this morning, I think you now have your answer.

Priced at 0.835p

Whilst you could make a case for it to be a worked buy or sell, there were few trades in the last couple of hours. So, given the price I would say it was a worked buy.

Either way, we will know at tomorrow's opening bell.

Rick you’re missing the part where the nominal value of each share will be changing from 1p to 0.005p so the bod can raise at 0.0075

The EAF151 Phase II trial enrolling 146 patients across 33 medical centres evaluated how well the company's IB Neuro platform could track patient responses to Bevacizumab. Bevacizumab is a widely used but highly expensive drug for treating recurrent glioblastoma an incredibly aggressive form of brain cancer.  The trial proved that IB Neuro’s fully automated tracking tool (sRCBV) provided an objective, early response signal within weeks rather than months. Crucially, its automated mapping showed a stronger statistically significant association with overall survival rates than standard manual tracking.  Because the platform can tell clinicians whether a costly treatment is actually working within a few weeks, it holds immense financial value for healthcare providers and clinical trial operators. It allows doctors to stop ineffective treatments early, saving patients from unnecessary side effects. Cut wasteful healthcare spending on expensive therapies that aren't working.  Rapidly pivot patients to alternative treatments or clinical trials when time is of the essence. Investors are particularly responsive to how a company intends to make money off its wins. Alongside the clinical data, Imaging Biometrics laid out a clear commercial strategy targeting the very sites that participated in the trial, alongside global trial organisations. 

Management highlighted that this rollout is capital-efficient. Because the existing infrastructure is already built and the software is already FDA-cleared and CE-marked, they can generate incremental organic revenue without needing massive external funding or dilutive capital raises. For a micro-cap stock, a clear path to revenue that doesn't involve printing new shares is an immediate green flag for the market. 🚀💰🚀💰🚀💰🚀💰🚀💰📈📈

Spread much tighter than on here, it is 0.83/0.93, time to load up.

Nice buy of 480,520 just gone through, will be an interesting afternoon

Only 0.93 to buy, think it was more on Friday

Big recovery play here - potential is amazing

Let’s see if the MM’s are still going to do a massive spread today. The question is how many people have sells fixed in at 1p? If we could get above that it may free some stock up and then we can see a few sells/buys. At the moment nobody will sell at this price.

It’s upto to the MMs to create interest in the stock now.

Thanks

🤞. Surely not a hard sell now .

Thanks Max

So that implies the 33 sites should hopefully starting using our technology and pay for it. Fingers crossed.

Thank you

Tyke

The trial was a 5 year grant fund

Imaging Biometrics (IB), was awarded a US$2.57mln, five-year grant from the National Institutes of Health (NIH) – National Cancer Institute (NCI). From 2020

I wonder how many of these 30+ sites will actually start paying for IB Neuro now? Did they actually pay for it during the trial I wonder, if so will there actually be any increase in usage/revenue from those sites? Do we need other sites to sign up to increase our revenue from existing values. If it is bundled in via GEHC how much will IBAI see as profit?

Lots of questions but unfortunately no answers yet. Hopefully the interim results will provide more of an idea.

Thanks XV and Max

What EAF151 Means for IB Neuro™ & Bevacizumab Decision-Making in Recurrent GBM

EAF151 (Abstract), a prospective phase 2 clinical trial (33 sites, n=146), was designed to evaluate whether dynamic susceptibility contrast MRI-derived relative cerebral blood volume, or rCBV, could serve as an early imaging biomarker of response to bevacizumab in patients with recurrent GBM.

This is especially important because bevacizumab can produce imaging changes that make conventional MRI interpretation more challenging, including reductions in enhancement that may not represent the true underlying tumor biology.

In the EAF151 analysis, IB Delta T1 maps were used in all exams to identify true regions of contrast enhancement. Then, IB Neuro computed both normalized and standardized rCBV metrics. While both were shown to be significant, standardized rCBV (exclusive to IB Neuro) demonstrated a stronger statistically significant overall survival signal, while also offering the clinical advantage of fully automated and more consistent processing.

For clinicians, the takeaway is clear:

When treatment decisions are complex, qualitative imaging alone may not be enough.

IB Neuro translates DSC-MRI perfusion data into objective, consistent and reproducible metrics that can support:

Earlier insight into treatment response

More informed bevacizumab decision-making

Standardized rCBV analysis across MRI platforms

Automated workflows that reduce manual post-processing burden

Greater confidence when conventional imaging is ambiguous

In recurrent GBM, timing matters!

XV

33 sites involved in the EAF151 trial. I hope we hear more about it. Add that to the share options it starts to make sense and hopefully will see the sp increase if the MMs will finally raise the sp to somewhere near a realistic valuation.

Thanks

I wonder if there is more news - re IB Neuro - to come

i would not be surprised.

Cautious

I think it is more to do with nobody is going to sell at this ridiculous low price. Anybody who has looked into the company know its technology is worth many multiples of its current mcap. However, no MM is willing to take the risk (because of previous shenanigans?) and raise the sp, currently. Hopefully that will change. Let’s see if Mr Big is correct about an after hours big buy being reported then that might lead to a good Monday.

Thanks

_Mr_Big

If that is your delayed buy (466k @ 0.85p) that's a very good price?

Will be interesting to see what happens next.

I know it is only 100 shares but 1p just paid

Thanks

So if we don’t have a big buyer, then a few people take their profit, could we possibly end in the “red” today. I would say that would be funny given the RNS but I don’t want people getting upset by it again.

The company is moving forward with the imaging side as they said but the sp never follows suit.

Thanks

I suspect they are filling a buy order.

Will any MM raise the sell to 1p+?

Then we could have a buying and selling spree but will any of them risk it? I doubt it. Nobody is selling at this price only a few traders making their 10%. We can’t blame the BoD for this. The company have done their bit will the MMs do their bit?

Thanks

FFS that is not the true spread, what is wrong with people.

Morning Semantic

Nice to hear from you, I hope you are well. A great RNS that explains the staff share options more. Congratulations to all the team.

The RNS make explain the lack of tweets from the conference (new MO?). Let’s see if any of the missing 150m shares suddenly appear and start being traded.

Hopefully this will lead to an increase in the sp but history shows that is not always the case.

Have a good weekend everybody

Thanks

Ahaaa Semantic !!

Where have you been !!

Ah...wait...is the study that dates back to....2017?

too early to put the pieces together

but sounds like good news...

I is awake. but was thinking....is this EAF151 related to the expanded access program...

same thing?

thanks.

Wake up!

HGGGCG

Ha ha ha, 'not had a pumped share for ages', that has started my day off with a smile, very funny.

Hopefully onwards and upwards. TB is getting on, and has not had a pumped share for some time. This could be it.

A major US trial selected and loved IBAI's software

we are validated

externally validated

that is great news

🔵RNS OUT

Cautious

That fits in with what we have seen before

Approx 75m Truetide

10m KS/MS

16m which equates to those who have joined together before.

The other 150m, who knows? It’s the same as somebody keeps buying 1 share and then upping it to two shares when I said it was the same price. There is no rhyme or reason. This share is an enigma, hardly any trading of it and only a few of us seems to have enough of an opinion to vote.

There must be literally hundreds of long term shareholders who have just forgotten about them or written them off as a 90% etc loss. Heads in sand or honestly are just hopefully waiting for this to make their money back.

Quite a few people seem to follow what TB invests in as their own strategy (if you read some comments on Truetide). Yes they may show a paper loss but things can change rapidly and they know when to cash out and/or wait for the special dividend.

Unfortunately we are the paper loss currently. Could this all change? Yes but then again we may remain at this valuation for many more months or years. I am waiting for the interims to see what the revenue actually is. There will be no hiding place if there is not, to use their words, a step change. If Mallettp’s reading of the GaM phase 0 is correct then I don’t think we will get an update or possible sale of the data this year.

Thanks